Merck & Co. Inc. has announced that because of a continuing manufacturing issue, its shortage of pediatric hepatitis B (HepB) recombinant vaccine (Recombivax HB) will continue through the rest of 2018.
On its Current Vaccine Shortages & Delays webpage,(www.cdc.gov) the CDC said GlaxoSmithKline will mitigate the shortage of pediatric HepB vaccines with supply to meet full demand in the United States.
GSK will do so using its monovalent pediatric HepB vaccine (Engerix-B Pediatric) and its diphtheria, tetanus toxoids and acellular pertussis (DTaP); HepB; and inactivated polio vaccine (IPV) pediatric combination vaccine (Pediarix).
Merck hasn’t distributed its pediatric HepB vaccine since mid-2017 and has informed the CDC that it will have only a limited supply available for the rest of the year.
The combined supply from the two manufacturers should account for about 90 percent of the amount of monovalent pediatric HepB vaccine normally available for the rest of 2018, said the CDC.